### Implementation and Outcomes Research

#### Contact Information
Applicants who are interested in this RFP are encouraged to submit your name and email address to grants@wacarefund.org to request your organization receive any amendments and question and answer documents. As applicable, amendment and question and answer documents will be posted to the CARE Fund website.

Any questions regarding this grant announcement should be submitted to grants@wacarefund.org. Questions will be answered in writing and posted to the website.

#### Program Purpose
This grant opportunity is intended to support innovative investigators from eligible organizations to translate promising research and scientific discoveries into the development of tools, devices, technologies, therapeutics, or interventions related to cancer that have the potential to address cancer care across the implementation/translational cancer research continuum that will ultimately advance cancer care, lessen the burden of cancer, and improve health outcomes. Projects that include a provision of services that includes quantifiable outcomes data suitable for efficacy research are eligible.

#### Application Deadline
August 13, 2024 (5:00 p.m. PT). Application submitted online, which is available on the grant opportunity page on CARE Fund website.

#### Project Period
Up to 2 years, expected start date April 1, 2025.

#### Award Amount
$250,000 to $1,500,000 for project duration, inclusive of direct and indirect costs. Grant requires a one-to-one (1:1) non-state match to grant award.

#### Eligible Applicants
Organizations eligible to apply for and receive grants include but are not limited to Washington State companies, higher education institutions, research institutions, local health jurisdictions, tribal governments, tribal entities, nonprofit institutions, and Urban Indian Organizations. Organizations may submit up to five (5) applications for this funding opportunity, but a Principal Investigator may not submit more than one application.

---

**ANDY HILL CANCER RESEARCH ENDOWMENT**

The Andy Hill Cancer Research Endowment (CARE) Fund was established in 2015 by the state legislature as a bold public-private partnership to promote cancer research in Washington. With the establishment of the CARE Fund, the state is making a commitment to support the cancer research ecosystem with sustained investment to promote cancer research aimed at improving the quality of life of the people of Washington.
The objectives of the Andy Hill CARE Fund (from RCW 43.348.005) include the following:

- Optimize the use of public funds by giving priority to research utilizing the best science and technology with the greatest potential to improve health outcomes;
- Increase the value of our public investments by leveraging our state’s existing cancer research facilities and talent, as well as clinical and therapeutic resources;
- Incentivize additional investment by requiring private or other non-state resources to match public funds;
- Create jobs and encourage investments that will generate new tax revenues in our state; and
- Advance the biotech, medical device, and health care information technology industries in Washington.

I. OVERVIEW AND SCOPE

This grant opportunity is intended to support innovative investigators from companies, research institutions, and other eligible organizations to translate promising research and scientific discoveries into the development of tools, devices, technologies, therapeutics, or interventions related to cancer. This request for proposal (RFP) seeks applications that are focused on the development and implementation or translation of innovative ideas that have the potential to address important needs related to cancer prevention, screening, detection, treatment, and survivorship and that will ultimately advance cancer care, lessen the burden of cancer, and improve health outcomes.

Proposed projects should be focused on implementing or translating research findings into a cancer-related product or technology or evaluating the outcomes of implementing scientific discoveries in cancer research. Projects may be anywhere along the implementation translational cancer research continuum, from proof-of-concept research to product launch and commercialization to implementation of an intervention. Projects should be additive to current understanding and seek to create new knowledge. Projects that include a provision of services that includes quantifiable outcomes data suitable for efficacy research are eligible.

A portion of administrative costs for essential product development and commercialization activities may be allowed but only if they are not the primary focus of the project. Projects that primarily seek funding for advertisement and promotion for commercialization, without seeking to create knowledge, are not aligned with the program’s purpose.

II. APPLICATION CHARACTERISTICS

Eligibility

- Organizations eligible to apply for and receive grants include but are not limited to Washington State companies, higher education institutions, research institutions, local health jurisdictions, tribal governments, tribal entities, nonprofit institutions, and Urban Indian Organizations. Applicants must have a substantial presence in Washington, as determined by CARE Fund based on factors including, but not limited to: the number and type of staff in Washington; state of incorporation; location of headquarters, research, or manufacturing facilities in Washington; or any combination of such factors.
- Organizations may submit up to five (5) applications for this funding opportunity, but a Principal Investigator may not submit more than one application.
• This announcement is open to all cancer-related research proposals.

Grant Matching Fund Requirements
• Applicants must submit proof of their secured minimum one-to-one (1:1) match of non-state of Washington funds to requested grant funds. The required matching funds must be secured at the time of the award agreement execution. Examples of eligible non-state match sources include, but are not limited to, federal grants, sponsored research agreements, in-kind resources, and unrecovered indirect costs.

Grant Award and Use of Funds
• The project period may be up to two years (24 months); Budget expenses may be allocated over the project period as needed, commensurate with the timeline and milestones.
• The total grant request (direct and indirect costs) over the project period may not exceed $1,500,000 and may not be less than $250,000. Grant payments will be made no more frequently than monthly as reimbursement on actual expenditures.
  o The amount of funding requested should reflect the scope of the project and the appropriate budget for a two-year project period. The maximum award amount is not an indication of the ideal project size, rather it is an award size limit. CARE Fund is interested in innovative projects of all sizes. Requests for smaller grants are allowed and encouraged.
  o Grant funds may be used to directly support a project, serve as matching funds, or support costs related to product development, validation, or launch, and secure funding or support costs related to product development and commercialization including associated business support (e.g., grant writing, regulatory support, legal services, accounting, etc.).
  o Grant funds may be used to purchase capital equipment, but the equipment must be essential to achieve the research or product development aims as detailed in the project research plan.
• Projects with collaborations outside of Washington State are allowed; however, the majority of the CARE Fund grant award and required non-state match contribution must be allocated to recipients conducting research in Washington State. Only a minority of the CARE Fund grant funds awarded to the Washington State entity may be provided to out-of-state researchers and entities as required to complete the project awarded the grant.
• All grants will be made in accordance with the CARE Fund’s policies and applicable laws, including the CARE Fund statute (Chapter 43.348 Revised Code of Washington).

III. TIMELINE AND APPLICATION PROCESS
Applications must be submitted through the CARE Fund grants management system, which can be accessed via the CARE Fund website. The grant application will be available to applicants by Wednesday, June 12, 2024, and the application must be submitted by Tuesday, August 13, 2024, 5:00 p.m. (PT).

The application prompts and questions are available on the Implementation and Outcomes Research page on the CARE Fund website.

Award decisions for this opportunity are anticipated to be made by February 28, 2025. Applicants will be notified of award decisions via email.
**Estimated Timeline**

<table>
<thead>
<tr>
<th>Event</th>
<th>Date/Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Call for Proposals Announced</td>
<td>Jun 12, 2024</td>
</tr>
<tr>
<td>Application Deadline</td>
<td>Aug 13, 2024</td>
</tr>
<tr>
<td>Independent Scientific Peer Review</td>
<td>Oct–Dec 2024</td>
</tr>
<tr>
<td>CARE Board Award Decision</td>
<td>Feb 2025</td>
</tr>
<tr>
<td>Award Agreements Executed</td>
<td>Mar 2025</td>
</tr>
<tr>
<td>Anticipated Start Date</td>
<td>Apr 2025</td>
</tr>
<tr>
<td>Project Support</td>
<td>Up to 2 years (24 months) from project start date</td>
</tr>
</tbody>
</table>

CARE Fund reserves the right to revise the above schedule.

**Application Review Process**

**Stage 1: Application Review**
CARE Fund and/or contractors will screen the applications to assess the following:
- Does the application contain all required elements?
- Is the applicant eligible to apply under this funding opportunity?
- Is the proposed project appropriate and responsive for this funding opportunity?
- Does the proposed project have the potential to meet CARE Fund objectives and priorities?

If all questions above are answered “Yes,” the application will move to Stage 2: Peer Review. An application may be returned to the Applicant for completion or clarification, then re-submitted, per the judgment of the CARE Fund Executive Director.

**Stage 2: Peer Review**
Independent peer review will be conducted by the American Institute of Biological Sciences (AIBS), or a comparable organization. AIBS, or a comparable organization, will recruit a panel of independent, expert, scientific reviewers with expertise in the relevant areas of cancer research. Reviewers will initially evaluate the merit of the applications against the review criteria listed below. The review panel will then meet to discuss the initial review findings, taking into consideration CARE Fund program objectives and priorities, to arrive at final scores and ratings for each application. Reviewers will summarize the review results for each application in a final review, which will include a justification of the final scoring, rating, and ranking (when applications are ranked) of the applications in the cohort.

The CARE Board will be provided with the final reviews, the cohort’s ranked scores (when available) and associated ratings, and a narrative summary of the review panel’s funding recommendations.

**Stage 3: CARE Board Assessment and Award Decision**
The CARE Board will make award decisions based on the scores and recommendations made by the independent scientific reviewers and will ensure that reviews align with the CARE Fund objectives and priorities. When deciding between applications of similar merit, the CARE Board may also consider program objectives and priorities, including but not limited to cancer research discipline, type of cancer, or geographic distribution of grantee organizations. The CARE Board will act in accordance with its Conflict-of-Interest Policy as well as Chapter 42.52 RCW (Ethics in Public Service) to avoid actual, potential, or perceived conflict of interest.
IV. **APPLICATION REVIEW CRITERIA**

Eligible applications will be evaluated against each of the following criteria for an Overall Impact Score. All three factors will be considered in arriving at the overall impact score. The criteria factors serve to focus reviewers on three central questions when evaluating the application:

1. How important is the proposed research?
2. How rigorous and feasible are the methods?
3. To what degree do the investigator(s) and institution have the expertise and resources necessary to successfully carry out the project?

**Overall Impact**

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, major influence on the cancer research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

**Review Factors**

Reviewers will evaluate Factors 1, 2 and 3 in the determination of scientific merit, and in providing an overall impact score. In addition, Factors 1 and 2 will each receive a separate factor score. An application does not necessarily need to be strong in all categories to be judged likely to have a major scientific impact.

**Factor 1. Importance of the Research** (Score 1-9)

**Significance**

- Evaluate the importance of the proposed research in the context of current scientific challenges and opportunities, either for advancing knowledge within the field, or more broadly.
- Assess whether the application addresses an important gap in knowledge in the field, would solve a critical problem, or create a valuable conceptual or technical advance.
- Evaluate the rationale for undertaking the study, the rigor of the scientific background for the work (e.g., prior literature and/or preliminary data) and whether the scientific background justifies the proposed study.

**Innovation**

- Evaluate the extent to which innovation influences the importance of undertaking the proposed research. Note that while technical or conceptual innovation can influence the importance of the proposed research, a project that is not applying novel concepts or approaches may be of critical importance for the field.
- Evaluate whether the proposed work applies novel concepts, methods or technologies or uses existing concepts, methods, and technologies in novel ways, to enhance the overall impact of the project.

**Factor 2. Rigor and Feasibility** (Score 1-9)

**Approach**

- Evaluate the scientific quality of the proposed work.
- Evaluate the likelihood that compelling, reproducible findings will result.
- Assess whether the proposed studies can be done well and within the timeframes proposed (feasibility).

**Rigor**

- Evaluate the potential to produce unbiased, reproducible, robust data.
Evaluate the rigor of the experimental design and whether appropriate controls are in place.
Evaluate whether the sample size is sufficient and well-justified.
Assess the quality of the plans for analysis, interpretation, and reporting of results.
Evaluate whether the application includes adequate plans to address relevant biological variables, such as sex or age, in the design, analysis, and reporting.
For applications involving human subjects or vertebrate animals, also evaluate:
- the rigor of the intervention or study manipulation (if applicable to the study design).
- whether outcome variables are justified.
- whether the results will be generalizable or, in the case of a rare disease/special group, relevant to the particular subgroup.
- whether the sample is appropriate and sufficiently diverse to address the proposed question(s).
For applications involving human subjects, including clinical trials, assess the adequacy of inclusion plans as appropriate for the scientific goals of the research. Considerations of appropriateness may include:
- disease/condition/behavior incidence, prevalence, or population burden, population representation, and/or current state of the science.
- ability to offer trial participants information in a language other than English.
- ability to provide culturally specific recruitment materials alongside general enrollment materials.
- ability to provide electronic consent when not prohibited by other granting entities or federal regulations.
- other evidence of outreach and engagement to increase participation of underrepresented communities in clinical trials of drugs and medical devices.

Feasibility
Evaluate whether the proposed approach is sound and achievable, including plans to address problems or new challenges that emerge in the work. For proposed studies in which feasibility may be less certain, evaluate whether the uncertainty is balanced by the potential for major advances.
For applications involving human subjects, including clinical trials, evaluate the adequacy and feasibility of the plan to recruit and retain an appropriately diverse population of participants. Additionally, evaluate the likelihood of successfully achieving the proposed enrollment based on age, racial, ethnic, and sex/gender categories.
For clinical trial applications, evaluate whether the study timeline and milestones are feasible.

Factor 3. Expertise and Resources (not scored) - Sufficient/Insufficient
Investigator(s)
Evaluate whether the investigator(s) have demonstrated background, training, and expertise, as appropriate for their career stage, to conduct the proposed work. For Multiple Principal Investigator (MPI) applications, assess the quality of the leadership plan to facilitate coordination and collaboration.

Environment
Evaluate whether the institutional resources are appropriate to ensure the successful execution of the proposed work.
V. **RATING**

<table>
<thead>
<tr>
<th>Rating</th>
<th>Description of Rating</th>
<th>Overall Impact Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highly Recommended</td>
<td>Demonstrates high potential to impact the field of cancer research or cancer care and strong scientific merit and approach. Meets the stated goals and objectives of the funding opportunity. Extremely well-constructed Proposal.</td>
<td>1-3</td>
</tr>
<tr>
<td>Recommended</td>
<td>Demonstrates potential to impact the field of cancer research or cancer care and strong scientific merit and approach. Meets the stated goals and objectives of the funding opportunity. Well-constructed Proposal.</td>
<td>4-6</td>
</tr>
<tr>
<td>Not Recommended</td>
<td>Demonstrates major weaknesses that will likely decrease the potential for successful completion of the proposed project and impact in the field of cancer research or cancer care. Limited potential to meet the stated goals and objectives of the funding opportunity. Unsatisfactorily constructed Proposal.</td>
<td>7-9</td>
</tr>
</tbody>
</table>

VI. **INTELLECTUAL PROPERTY**

Grantees must certify that they have policies in place regarding ownership and management of intellectual property and its protection. Grantees must report all inventions, whether or not patented or patentable or copyrighted or copyrightable, that are developed through CARE grant-funded activities or research projects to the CARE Fund in a timely manner. The CARE Fund does not intend to assert ownership of any invention that is derived from CARE funded research. However, if the grantee organization, or any subcontractor, decides not to take title and file an application for intellectual property protection, the CARE Fund would then have the option to take title. The grantee must notify the CARE Fund prior to any publication of the invention so as to allow the CARE Fund to take title and pursue or maintain intellectual property protection.

The CARE Fund does not expect to require payback of grants awarded based on income generated from sale or commercialization of any inventions resulting from CARE grant-funded activities or research. This approach is intended to minimize intellectual property-related barriers for potential applicants and encourage pursuit of transformational research. Successful projects will stimulate economic development through job creation and infusion of additional research funds to Washington. Products derived from these inventions will then be available to the public, with the expectation that it will improve health outcomes for the people of Washington and globally.

The CARE Fund must be listed as a funder in all presentations, publications, and patent applications.

VII. **CONFIDENTIALITY**

Information in grant applications is received by the CARE Fund with the understanding that it shall be used or disclosed for the evaluation of applications or as required by law. The CARE Fund holds all applications confidential in accordance with its confidentiality policy and or the confidentiality policy of its program administrator, subject to public disclosure laws of the state of Washington and other applicable laws. All applicants are advised that information provided to the CARE Fund,
including an applicant’s proprietary and confidential information, are considered public records under Washington’s Public Records Act, Chapter 42.56 RCW. Generally, public records are subject to disclosure unless an exemption to disclosure applies. Information provided to the CARE Fund may be protected from potential Public Records request disclosure under RCW 42.56.270(29), to the extent applicable in the CARE board’s sole discretion.

The CARE Fund may make use of information contained in applications for purposes of transparency and publicity, including, but not limited to: applicant name; applicant organization; project title; funding amount requested; and applicant profile. For unfunded applications, the CARE Fund will not publicly release the abstract or narrative of the proposed work, budget details, or any identifiers regarding co-applicant organizations, to the extent disclosure of this information might reasonably be expected to result in private loss to the applicant organizations, and as is consistent with public disclosure laws of the state of Washington or as otherwise required by law. If a proposal is funded, the CARE Fund may make public additional information from the application, including, but not limited to, project abstract; funding amount; names and profiles of the investigators or collaborating organizations.

The CARE Fund reserves the right to publicly disseminate information about a grantee’s activities through public reports, online, social media, press releases, speaking engagements, and other public venues. To the extent allowable under Washington State law or other applicable law, the CARE Fund shall not publicly disclose information that has been marked as proprietary or confidential if such information has not been previously disclosed to the public, or other information to the extent that provision of such information would reasonably be expected to result in private loss to the providers of such information.

VIII. CONTACT INFORMATION

Please email any questions regarding this grant announcement to: grants@wacarefund.org.

Full Application (Required)

Applicants must submit a full application through the CARE Fund’s online grants system. The full Implementation and Outcomes Research grant application is available to applicants on the CARE Fund website. The full application must be submitted by Tuesday August 13, 2024, 5:00 p.m. (PT). The online application form will include the prompts and questions listed below. [Note: Applicants should consider protecting any potential intellectual property or confidential information before disclosing it in the application. Proprietary, privileged, confidential commercial, patentable ideas, trade secrets, etc. should only be included in the application to the extent necessary to convey an understanding of the research project proposal. Such information should be clearly marked in the application materials as confidential, proprietary, or privileged information.]

---

1 All applicants to CARE Fund Grant Programs are advised that information provided to the CARE Fund, including an applicant’s proprietary and confidential information, are considered public records under Washington’s Public Records Act, Chapter 42.56 RCW. Generally, public records are subject to disclosure unless an exemption to disclosure applies. Much of the information provided to the CARE Fund may be protected from potential Public Records request disclosure to the extent provided under RCW 42.56.270(29). RCW 42.56.270(29) is an exemption in the Public Records Act that applies specifically to records provided in the context of a CARE Fund application and grant implementation. It exempts “Financial, commercial, operations, and technical and research information and data submitted to or obtained by the
Please respond to the following prompts and questions in the online application. (Application uploads should follow NIH font, line spacing, paper size, and margin guidelines. [https://grants.nih.gov/grants/how-to-apply-application-guide/format-and-write/format-attachments.htm#font](https://grants.nih.gov/grants/how-to-apply-application-guide/format-and-write/format-attachments.htm#font))

- **Acknowledgment of Grant Payment Conditions.** The applicant must review and acknowledge the conditions of CARE Fund grant award payments.
- **Applicant Organization Type.** Select the organization type that best describes your organization.
- **Applicant Organization Corporate Status.** Select the organization’s corporate status.
- **WA State OMWBE Certified Business.** Is the applicant organization a Washington State certified minority-, women-, or veteran-owned business? (This information is requested for measurement purposes only and it will not be used for evaluating the application.)
- **WA State Presence.** Does the Applicant Organization have a substantial presence in Washington State?
- **Project Title.** (250 characters or less)
- **Contact Person for this Application** (Enter First Name, Last Name, Position, Email)
- **Principal Investigator** (Enter First Name, Last Name, Title, Institution, Email) Enter the name of the Lead Principal Investigator. (If there are Co-PIs, list only one here.)
- **Layperson Summary of the Project.** Please provide a brief summary of the project using plain language suitable for non-scientific audiences. **Note:** The information provided in this section may be made publicly available, exactly as provided. Do not include proprietary information in the Layperson Summary. (750 characters or less)
- **Project Scientific Abstract.** Provide a summary of the proposed project for scientific audiences. **Note:** The information provided in this section may be made publicly available. Do not include proprietary information in the Project Scientific Abstract. (2000 characters or less)
- **Project Performance Site(s).** Provide the primary performance site for this proposal, and any other performance site(s). For each site, provide the organization’s legal name and location (city and state). (2500 characters or less)
- **Cancer Disparities.** Does the proposed project address cancer disparities? Cancer health disparities are adverse differences between certain population groups in cancer measures, such as: incidence, prevalence, morbidity, mortality, survivorship and quality of life after cancer treatment, burden of cancer or related health conditions, screening rates, and stage at diagnosis. These population groups may be characterized by race, ethnicity, disability, gender and sexual identity, geographic location, income, education, and other characteristics. Please...

---

Andy Hill Cancer Research Endowment program in applications for, or delivery of, grants under Chapter 43.348 RCW, to the extent that such information, if revealed, would reasonably be expected to result in private loss to providers of this information." However, applicants should be aware that their information will be subject to disclosure unless this or another exemption applies.

The applicant may be notified of any public records request regarding their application and be given an opportunity to provide further information specifying why the information should be exempt from disclosure, and an opportunity to assert objections to disclosure and seek a protective order. The CARE Fund will determine, in its sole discretion, whether to assert RCW 42.56.270(29) or any other available public records exemption.
refer to https://www.cancer.gov/about-cancer/understanding/disparities for more information.

- **Cancer Disparities Description.** Describe the cancer disparities the project will address. If none, enter N/A. (500 characters or less)

- **Childhood Cancer.** Is the primary focus of the proposed project on childhood cancer or childhood cancer issues?

- **Research Area.** Select the area of research that best characterizes the project included in this application. After selecting your research area, you will be asked to select the primary area of research focus. Please refer to https://www.icrpartnership.org/cso to see the research areas and primary areas of focus for each research area.

- **Cancer type.** Select the type of cancer that is the primary focus of the proposed project. Primary focus indicates that the majority of the project workplan is dedicated to research on the selected cancer type. Please refer to https://www.cancer.gov/types to identify common cancer types.
  - For projects which devote significant resources in the project workplan to more than one cancer type please select Multiple Types and specify the cancer types. (150 characters or less)
  - For research that applies to cancers regardless of tumor origin, select Pan-Cancer and describe. (250 characters or less)
  - If the cancer type is not among the common cancer types listed, please select Other and specify. (150 characters or less)

- **Proprietary/Privileged Information.** Is proprietary/privileged information included in this application? [Note: Applicants should consider protecting any potential intellectual property or confidential information before disclosing it in the application. Proprietary, privileged, confidential commercial, patentable ideas, trade secrets, etc. should only be included in the application to the extent necessary to convey an understanding of the project proposal. Such information should be clearly marked in the application materials as confidential, proprietary, or privileged information.] (See Washington State Public Records Act Notice)

- **Human Subjects.** Does the proposed project involve Human Subjects?
  - If yes, Institutional Review Board (IRB) status. (Approved/Pending/Exempt/Not Applicable)
  - IRB Approval Date
  - Human Subjects Assurance Number
  - Human Subjects Assurance. If applicable, describe the strategy for protection of human subjects (2000 characters or less)

- **Vertebrate Animals.** Does the proposed project involve the use of vertebrate animals?
  - If yes, indicate if the Institutional Animal Care and Use Committee (IACUC) review is pending or approved.
  - IACUC Approval Date (Leave blank if the IACUC approval is pending.)
  - Animal Welfare Assurance Number (Enter the number for the applicant organization)
  - Vertebrate Animal Welfare Assurance If applicable, provide sufficient information to demonstrate to reviewers that designation of vertebrate animal involvement is appropriate. (1500 characters or less)

- **Project Work Plan.** The project proposal should address the Review Criteria being evaluated by the review panel as outlined in the RFP which can be found on the IOR page on the CARE Fund web site, and include: (Upload, Limit 8 pages, including figures. References not included in the page limit. Maximum upload allowed: 15 MiB.)
- Importance of Research
  - Significance
  - Innovation
- Rigor and Feasibility
  - Approach
  - Rigor
  - Feasibility
- Expertise and Resources
  - Investigator(s)
  - Environment

- Project Milestones and Timeline. Use the Project Milestones and Timeline Guidance as a template to describe the project’s milestones, deliverables/outcomes, and completion dates. (Upload, Limit 4 page, 2 Mib allowed)
- Key Project Personnel. Use the Project Key Personnel Form to upload a list of key personnel including each person’s project role, name, position, and organization name. (Maximum upload allowed: 2 MiB)
- Biosketches for Principal Investigator and Key Personnel (Upload. NIH format, Limit 5 pages per biosketch, combine all biosketches as a single file. Maximum upload allowed: 15 MiB.)
- Project Support Period (Enter Start and End Dates). The earliest start date may not be before April 1, 2025. The end date may not be more than 24 months after the project support start date.
- Budget Narrative Justification. Use the Project Budget Narrative Justification Guidance as a template to create the budget narrative justification. (Upload, Limit 4 pages. Maximum upload allowed: 5 MiB.)
- Project Budget Direct Costs. For each budget category, enter the direct costs for the project across the entire project period into the table (i.e., months 1–12, months 13–24, and total). Please see the Project Budget Narrative Justification Guidance for a description of the direct cost budget categories.
- Project Budget Summary. Enter total direct, indirect and project costs across the entire project period, regardless of funding source into the table.
- Project Funding by Source. Enter the amounts of all funds from all sources for the entire project period into the table.
- Financial Commitment (Non-state match). Submit proof of commitment of the additional sources of funding (non-state funds or other funds) that have been secured. [Note: Proof of matching contributions may be accomplished by providing a written, binding, enforceable agreement from the contributor that commits an amount of non-state of Washington or private contributions. The document must include a definitive statement that a non-state or private contribution is committed, including the amount, AND acknowledge that the CARE Fund grant award is contingent upon this contribution.] (Maximum upload allowed: 4 MiB.)
- Project Team Interaction with End Users. Will the principal investigator or the project team interact with end-users (as defined by the researcher) of their research, resource, or product before, during, or after the proposed project?
  - Select all that apply
    i. Before project commencement
    ii. During the project
    iii. After project completion
  - If yes to any of the above, please describe. (1500 characters or less)